results 1568 isolates with recorded antimicrobial data were collected including 328 early-onset sepsis (EOS) isolates and 1240 late-onset sepsis (LOS) isolates. The majority of EOS pathogens (>92%) were susceptible to the four empirical commonly used antimicrobial combinations (eg, 93% for benzylpenicillin/gentamicin), while LOS pathogens demonstrated higher levels of resistance (eg, 89% for flucloxacillin/gentamicin). Among infants<1500 g and <32 weeks gestation, an amoxicillin/ gentamicin combination demonstrated a trend towards improved coverage of EOS isolates than benzylpenicillin/ gentamicin (93% vs 86%, p=0.211). Conclusions This analysis provides insights into the patterns of antimicrobial resistance among UK neonatal pathogens. These data will inform areas of future research and can be used to update national evidencebased guidelines on antimicrobial usage.
InTrODuCTIOn
Newborn babies are at a significant risk of infection during the neonatal period, especially those born prematurely or of low birth weight. 1 Neonatal infection is associated with considerable morbidity and mortality, being responsible for more than 250 neonatal deaths each year in the UK alone. [2] [3] [4] Infection during the neonatal period is classically divided into two distinct clinical syndromes based on the likely causative pathogens: early-onset sepsis (EOS) and late-onset sepsis (LOS). 4 5 The presentation of neonatal sepsis is typically non-specific, and empirical antimicrobial treatment is generally commenced before a causative organism is identified, and targeted therapy can be initiated. 6 It is therefore crucial to have a thorough understanding of the current epidemiology of neonatal infections in order to select the most effective and appropriate antibiotic combinations for empirical treatment. 5 The development and spread of antimicrobial resistance is now a major challenge in modern medicine, emphasising the importance of using antimicrobial agents appropriately and rationally. [7] [8] [9] There are now growing concerns that empirical treatment is increasingly likely to be inadequate in terms of antibiotic cover, especially in settings where there is a high prevalence of antimicrobial resistance. For example, recent modelling puts neonatal deaths due to resistant organisms in China, India, Pakistan, Nigeria and the Democratic Republic of Congo alone at 215 000 per year. 
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The objective of this analysis was to define the susceptibilities of the common causative pathogens
What is already known on this topic?
► Neonates with presumed sepsis require empirical antibiotic treatment before definitive culture results are available. A thorough understanding of epidemiology and resistance patterns is therefore imperative. ► The development and spread of antimicrobial resistance is an important issue in modern medicine. ► There is a paucity of new antibiotics to replace the current agents should they be rendered obsolete reinforcing the importance of choosing empiric combinations wisely.
What this study adds?
► A benzylpenicillin and gentamicin combination has very high coverage of early-onset sepsis pathogens in infants >32 weeks or >1500 g. ► For infants of lower gestation and birth weight, the combination of amoxicillin and gentamicin may provide better coverage. ► Clinicians should be vigilant in their assessment of the clinical effectiveness of the antimicrobial combination chosen in an individual neonate.
of neonatal sepsis in the UK and to provide guidance on empirical antimicrobial combinations. The epidemiology of infections in the neonIN network has been reported elsewhere.
MeThODs
neonIN collects data on all episodes of neonatal infection in participating neonatal units. An episode of neonatal infection is defined as a positive culture collected from the blood, cerebrospinal fluid (CSF) or urine (obtained via sterile technique), for which clinicians prescribed at least 5 days of appropriate antibiotics. Data are collected using a standardised online questionnaire that is completed by the clinician for each positive culture result. Repeatedly positive samples are considered to represent the same episode of infection unless they occurred more than 7 days after the last positive culture result. EOS is defined as infection occurring less than 48 hours after birth, while episodes thereafter are classified as LOS. This age cut-off was chosen as it most likely represents the transition between pathogens that are acquired via vertical and horizontal transmission; however, an analysis based on a 72-hour cut-off was also performed.
Antimicrobial susceptibility data were analysed against a predefined list of commonly used empirical antimicrobial combinations including those recommended by the British National Formulary for Children (BNFC) and the National Institute for Health and Care Excellence (NICE) EOS antibiotic guidelines (table 1) . 14 15 These choices are also consistent with the findings of a review of antimicrobial policies in use in UK neonatal units in 2008. 16 Organisms were deemed 'susceptible' if susceptible to at least one of the antibiotics in the combination and 'resistant' if resistant to all the constituent antibiotics individually. The exception to this occurred in cases where monotherapy was deemed to be inappropriate (eg, if an enterococcus isolate was recorded as 'susceptible' to gentamicin and there was no susceptibility data for flucloxacillin, then the culture was not listed as sensitive to the combination, as enterococci are intrinsically resistant to gentamicin). Otherwise, if susceptibility data were only available for one of the antimicrobial agents in the combination, then the pathogen was labelled as per the susceptibility of the antibiotic tested.
Data were extracted from the online neonIN database and imported into Stata V.14 for analysis. Statistical significance was defined as a p value of <0.05. Two methods were chosen to define the confidence of coverage estimates. First, 95% CI were calculated for each coverage estimate, and second, best-case and worst-case scenarios were calculated by classifying all isolates without complete antimicrobial resistance profiles as either sensitive or resistant, respectively. Finally, in recognition of the fact that antimicrobial susceptibilities may change over time, we conducted a further analysis of the data by comparing the two For 1568 of the 2667 isolates (59%), data were available on antimicrobial susceptibilities. Of these, 328 isolates represented EOS (62% of all EOS isolates) and 1240 LOS (58% of all LOS isolates). The vast majority of recorded isolates were blood cultures (91.3%), with urine obtained via sterile technique (4.9%) and CSF (2.2%) the other common sources. There were no significant differences between isolates for which susceptibility data were available and those for which they were not with regard to patient demographics (birth weight, gestational age or post natal age) (p>0.3 for all). Isolates were statistically significantly more likely to have a complete susceptibility profile if they were from blood cultures (online supplementary table 1).
Antibiotic susceptibilities to empirical combinations
The majority of EOS pathogens (>92%) were susceptible to the four empirical antimicrobial combinations tested. Cefotaxime monotherapy demonstrated a susceptibility rate of 98%. The BNFC combinations of benzylpenicillin and gentamicin or amoxicillin and cefotaxime demonstrated rates of 93% and 95%, respectively (table 2). 14 There was a statistically significant difference in the coverage of benzylpenicillin and gentamicin in comparison with cefotaxime monotherapy (p=0.037) but not for the other combinations.
LOS pathogens demonstrated higher levels of resistance than EOS pathogens. A combination of vancomycin and cefotaxime displayed coverage of 92% of isolates tested, while flucloxacillin and gentamicin covered 89% (table 2). 14 Amoxicillin and clavulanic acid provided significantly lower coverage than any other tested combination (p<0.02), while flucloxacillin and gentamicin were notably more effective as a combination for LOS than amoxicillin and cefotaxime (p=0.014). . This demonstrated statistically significant differences for several combinations, mostly reflecting an increase in susceptibility over time.
Carbapenem resistance was rare among the tested isolates with 97% demonstrating susceptibility. Acinetobacter sp., Pseudomonas sp. and Serratia sp. exhibited the highest levels of resistance (40%, 5% and 3%, respectively).
Extending the definition of EOS from 48 hours to 72 hours made no difference to the estimates of coverage for any combination tested, largely because so few isolates were obtained on day three (online supplementary table 3).
Antimicrobial susceptibilities of specific pathogens
Both BNFC-recommended EOS combinations had complete coverage of the most commonly isolated pathogen, group B streptococcus. There was no significant difference in the 
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coverage of the second most prevalent EOS pathogen, Escherichia coli, between penicillin and gentamicin (94%) and amoxicillin and cefotaxime (90%) (p=0.53). Enterococcal species had high susceptibility to an amoxicillin and cefotaxime combination (93%).
Among common LOS pathogens, E. coli exhibited susceptibility in approximately 85% of cases to both BNFC-recommended combinations. Enterococcus sp. demonstrated high susceptibility rates to amoxicillin and cefotaxime (95%), while the contrary was true of Enterobacter sp., which were significantly more likely to be susceptible to flucloxacillin and gentamicin (59% vs 82%, p<0.001). At least 88% of Klebsiella species were susceptible to each of these combinations (table 3) . The most prevalent individual organisms displaying resistance to common antimicrobial combinations are demonstrated in online supplementary table 4.
The E. coli associated with EOS were different to those associated with LOS. Of a total of 393 E. coli isolates reported, 258 (66%) had a complete antimicrobial susceptibility profile. Isolates causing LOS had significantly higher rates of antimicrobial resistance to a number of agents including amoxicillin and clavulanic acid (29% vs 16% for EOS), cefotaxime (16% vs 6%), ciprofloxacin (22% vs 3%) and gentamicin (15% vs 5%). High levels of resistance to amoxicillin/ampicillin (58%-63%) were observed for both EOS and LOS isolates. LOS E. coli isolates were also 2.5 times more likely to demonstrate multidrug resistance (ie, to at least three tested classes of antimicrobial agents) than those causing EOS (p=0.039).
Antimicrobial susceptibilities by birth weight and gestation at birth
The two BNFC-recommended EOS combinations demonstrated high rates of coverage of EOS pathogens for infants >1500 g and >32 weeks gestation (93%-99%). 12 However, these combinations demonstrated significantly lower coverage rates in very low birthweight (VLBW) infants (<1500 g) and the extremely preterm (<32 weeks) (79%-92%, p=0.013 and 0.003, respectively). An amoxicillin and gentamicin combination demonstrated comparable levels of coverage to the benzylpenicillin and gentamicin combination for all birth weight and gestational age categories, with a non-significant trend towards improved coverage in infants <1500 g and <32 weeks (93% vs 86%) (p=0.211) (online supplementary table 5).
For LOS, similar rates of coverage were seen across all birth weight and gestational age categories for each combination. For flucloxacillin and gentamicin, for example, the rates of coverage varied only from 86% to 92% (online supplementary table 5).
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DIsCussIOn
EOS pathogens showed high rates of susceptibility to all four of the tested empirical antimicrobial combinations. The levels of susceptibility to the two BNFC-recommended 14 combinations were approximately 95%, similar to those reported in previous UK studies. 17 18 Although high rates of susceptibility (95%-98%) were reported for the cefotaxime-based regimens, due to the broadness of their spectrum of coverage and propensity to induce resistance, there should be considerable reluctance to consider these as first-line empirical therapies for EOS. 16 19 The only exception to this would be the use of cefotaxime and amoxicillin in the setting of possible bacterial meningitis, due to the better CSF penetration associated with third-generation *Please note that while it may seem counterintuitive that these figures should differ, this is due to the fact that isolates where testing is done for one antibiotic in a combination but not the other are marked as susceptible or resistant according to that agent. Therefore, the difference between cefotaxime monotherapy and an amoxicillin and cefotaxime combination is due to isolates labelled as resistant to amoxicillin and for which cefotaxime is untested. As such, the isolate is labelled as resistant to the amoxicillin and cefotaxime combination but 'not tested' for cefotaxime monotherapy. Susceptibility levels (%) of early-onset and late-onset pathogens in the neonIN cohort to commonly used antibiotic combinations for the treatment of neonatal sepsis. Cefotaxime monotherapy demonstrated the highest rate of susceptibility for early-onset pathogens (98%), while the two most commonly used empirical combinations, benzylpenicillin and gentamicin or amoxicillin and cefotaxime, demonstrated rates of 93% and 95%, respectively. A combination of vancomycin and cefotaxime displayed the highest rates of microbial susceptibility among lateonset pathogens (91%) with the commonly prescribed combination of flucloxacillin and gentamicin demonstrating the second highest rate of coverage (89%). #, number of isolates; %, percentage of isolates, EOS, early-onset sepsis; LOS, lateonset sepsis. Number of isolates tested and susceptibility rate for the most prevalent pathogens of both (A) EOS and (B) LOS. Almost all the most common pathogens of EOS demonstrated high levels (≥90%) of susceptibility to both first-line antimicrobial combinations. Approximately 15% of E. coli isolates displayed resistance to both LOS combinations. #, number of isolates; %, percentage of isolates; BNFC, British National Formulary for Children; EOS, early-onset sepsis; LOS, late-onset sepsis.
cephalosporins. 20 It is also important to note that the absence of coverage of Listeria and enterococcal infections further reduces the effectiveness of cefotaxime monotherapy as a first-line choice for EOS.
While a benzylpenicillin and gentamicin combination had satisfactory coverage of EOS pathogens in infants >32 weeks or >1500 g, our results suggest that for infants of lower gestation and birth weight, the slightly broader spectrum combination of amoxicillin and gentamicin provides at least equivalent coverage, with a trend towards increased efficacy, in this population of neonates (93% vs 86%, p=0.211). This raises the possibility that the above combination should be the preferred option for first-line therapy in these more premature infants. As the majority of babies receiving empirical antibiotics for EOS are born at term, it is however important to continue to use the more narrow spectrum combination (benzylpenicillin and gentamicin), in this group, especially given the coverage or pathogens is very high.
As would be expected, because LOS pathogens are generally nosocomially acquired, the LOS pathogens demonstrated higher levels of resistance than EOS pathogens. The very broad spectrum combination of vancomycin and cefotaxime displayed coverage of over 91% of organisms tested. There should however be considerable reluctance in using this combination routinely given its high potential to develop antimicrobial resistance. 21 This policy is supported by the low mortality rate of coagulase negative staphylococcal infections 22 and the rarity of methicillin-resistant Staphylococcus aureus in our network. 21 In total, 89% of isolates were susceptible to flucloxacillin and gentamicin, while 85% were susceptible to amoxicillin and cefotaxime. 17 18 In fact, these values are not statistically significantly lower than for vancomycin and cefotaxime. LOS pathogens were similarly susceptible to flucloxacillin and gentamicin across all birth weight and gestational age categories, supporting the continued routine use of this narrow-spectrum combination as a first-line empiric therapy. 14 E. coli isolates associated with EOS had different antimicrobial resistance patterns to those causing LOS. LOS E. coli were more frequently associated with higher levels of antimicrobial resistance to a variety of common antibiotics including amoxicillin and clavulanic acid, cefotaxime and gentamicin. This suggests that the E. coli isolates associated with vertical transmission are different to those that are horizontally transmitted and supports the notion that they require treatment with different antimicrobial regimens. 18 For all infants, regardless of age at onset or gestation at birth, none of the antibiotic combinations tested provide complete coverage against all pathogens. This raises the question of what comparative levels of coverage are acceptable, an issue that should also take into account the individual pathogens that are missed and their intrinsic virulence. It also means that clinicians should be vigilant in their regular assessment of the clinical effectiveness of the antimicrobial combination chosen in an individual neonate. Infants that are deteriorating despite 'appropriate' empirical therapy should be reviewed and antibiotics changed rather than waiting for blood culture results. This concept is included in the NICE guidelines. 15 The primary strength of the neonIN database is its size and longitudinal design, incorporating 30 neonatal units over 10 years; however, a number of potential limitations must also be acknowledged. First, the infection definition may be considered too simplistic or subjective given its reliance on the clinician's judgement. This subjectivity may lead to over-reporting of cases, particularly of common skin contaminants. An alternative would be to incorporate more clinical and laboratory markers into the study definition, but this may then in turn affect the completeness and quality of data entered.
It is also important to acknowledge the fact that some antimicrobial combinations act synergistically (eg, benzylpenicillin and gentamicin) and that resistance to the constituent antimicrobial agents in a combination may not equate to resistance to the combination itself. 23 Conversely, it must be acknowledged that in some cases, the reported in vitro susceptibility to an antimicrobial agent does not mean that it is recommended for the treatment of that organism (eg, cephalosporins for enterobacter). Both these factors are difficult to account for and may affect the generalisability of the stated results.
The statistical analyses used may also provide a potential source of bias as we have converted raw susceptibility data into a more clinically relevant format, which is combination based. This may create issues in cases where testing is done for only one antibiotic, as the combination is therefore labelled as susceptible or resistant accordingly. For example, the difference between cefotaxime monotherapy and an amoxicillin and cefotaxime combination may be explained by isolates with a recorded susceptibility profile to amoxicillin alone (eg, resistant). As such, the isolate would be labelled as resistant to the combination but 'not tested' for cefotaxime monotherapy.
Data completeness is always a potential weakness. However, although only half of the pathogens had susceptibility data recorded, we have no evidence to suggest that these isolates were not representative. We also believe that the conclusions are relevant for all UK tertiary neonatal units as this reflects the case-mix found in the neonIN network, with units spread widely throughout England. We do however note the presence of dominant reporting centres, with 10 units providing data on >50 isolates. This may impact the generalisability of the data.
These results highlight a number of important areas for future research, particularly with respect to the use of risk factorbased guidelines for empirical antimicrobial policies. The introduction of such guidelines, for example, those proposed for infants <1500 g or <32 weeks gestation, would be of significant clinical value if further validated. Future research in this area would inform the development of a simple and clinically relevant guideline that could easily be implemented in neonatal units.
This study provides unique insights into the antimicrobial resistance patterns exhibited by the pathogens that commonly cause neonatal infections in tertiary UK neonatal units. It presents new data of clinical value that could provide direction for the development of novel risk factor-based guidelines for empirical antimicrobial treatment that may in turn lead to better health outcomes for our neonatal population.
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